Clinical trials: Bronchial Neoplasms
Carcinoma, Non-Small-Cell Lung
Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2
4 cycles of induction treatment with nab-paclitaxel and carboplatin followed by nab-paclitaxel monotherapy for those subjects who are progression free at the end of 4 cycles.
- Trial name
- AboundPS2 (NCT02289456)
- Testing
- nab-Paclitaxel, Carboplatin
- Where
- 8 sites in United States
- Volunteers
- 40 people
- Sponsor
- Celgene
Advanced Solid Tumor, Cholangiocarcinoma
To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
This is a Phase Ib/II, multicenter, open-label study to evaluate the safety and preliminary efficacy of TT-00420 tablet, as monotherapy or in combination regimens, in patients with advanced solid tumors (solid tumor, BTC and…
- Conditions
- Advanced Solid Tumor, Cholangiocarcinoma, Biliary Tract Cancer, HER2-negative Breast Cancer
- Trial name
- NCT05253053
- Testing
- TT-00420, Combination Product: Atezolizumab, Combination Product: Nab-Paclitaxel
- Where
- 9 sites in China
- Volunteers
- 84 people
- Sponsor
- TransThera Sciences (Nanjing), Inc.
Carcinoma, Non-Small-Cell Lung
Trial of Weekly Taxotere and Irinotecan (CPT-11) in Patients With Advanced Non-small Cell Lung Cancer
The main purpose of the study is to determine the activity of the weekly combination of docetaxel (Taxotere) and irinotecan in terms of response rate in subjects with advanced, previously untreated, non-small cell lung cancer.
- Trial name
- NCT00819728
- Testing
- Docetaxel, Irinotecan
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Sanofi
Brain Metastases, Non-small Cell Lung Cancer
SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI
Despite the impressive response rate to third-generation EGFR-TKIs, resistance inevitably develops in most patients. Stereotactic radiotherapy plays a growing role in the management of patients with brain metastasis.
- Trial name
- NCT06020066
- Testing
- EGFR-TK Inhibitor, Stereotactic radiotherapy
- Where
- China
- Volunteers
- 202 people
- Sponsor
- Fudan University
Advanced Solid Tumors (Part A/B/C/D), Non-small Cell Lung Cancer (Part E)
A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549
This dose-escalation study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of IPI-549 monotherapy and IPI-549 in combination with nivolumab in subjects with advanced solid tumors.
- Conditions
- Advanced Solid Tumors (Part A/B/C/D), Non-small Cell Lung Cancer (Part E), Melanoma (Part E), Squamous Cell Cancer of the Head and Neck (Part E)
- Trial name
- NCT02637531
- Testing
- IPI-549 (eganelisib), Nivolumab
- Where
- 11 sites in United States
- Volunteers
- 219 people
- Sponsor
- Infinity Pharmaceuticals, Inc.
Carcinoma, Squamous Cell of Head and Neck (HNSCC), Melanoma
A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab
This study is open to adults with advanced head and neck cancer, skin cancer, or non-small cell lung cancer. People can take part if previous treatments were not successful.
- Conditions
- Carcinoma, Squamous Cell of Head and Neck (HNSCC), Melanoma, Non-small Cell Lung Cancer (NSCLC)
- Trial name
- NCT05068102
- Testing
- BI 765063, Ezabenlimab, [89Zr]Zr- BI 765063
- Where
- Netherlands
- Volunteers
- 14 people
- Sponsor
- Boehringer Ingelheim
Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV
Pulmonary Rehabilitation in Advanced Lung Cancer Survivors
This study is for people who have previously been diagnosed with advanced stage non-small cell lung cancer (NSCLC). Many people with advanced stage NSCLC have trouble breathing and feel tired.
- Conditions
- Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer, Lung Cancer
- Trial name
- NCT07104630
- Testing
- Pulmonary Rehabilitation (PR), No intervention: Usual care
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Case Comprehensive Cancer Center
ASTHMA
Risk Factors Associated to Difficult-to-control Asthma
Several studies have demonstrated the efficacy of asthma treatment but despite being correctly diagnosed, conveniently prescribed and adherent to the therapeutics, 5% to 10% of asthmatics do not reach disease control.
- Trial name
- NCT01089322
- Testing
- inhaled corticosteroid plus LABA plus oral corticosteroid
- Where
- Brazil
- Volunteers
- 74 people
- Sponsor
- Rafael Stelmach
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung Cancer
Phase II trial to study the effectiveness of combining bortezomib with gemcitabine and carboplatin in treating patients who have advanced or recurrent non-small cell lung cancer that has not been previously treated with…
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00075751
- Testing
- gemcitabine hydrochloride, carboplatin, bortezomib
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- National Cancer Institute (NCI)
Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases
An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases
This is a multi-center, single-arm, open-label, Phase 2 clinical study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases.
- Trial name
- NCT04339829
- Testing
- Dacomitinib
- Volunteers
- 50 people
- Sponsor
- Guangdong Association of Clinical Trials
Carcinoma, Non-small Cell Lung
Genomic Profiling in Previously Untreated Metastatic Non-small Cell Lung Cancer
Overall survival rates for patients with metastatic NSCLC are poor utilizing conventional cytotoxic chemotherapy approaches. However, a subset of patients harbor genomic driver mutations, which when targeted with specific…
- Trial name
- NCT02671045
- Testing
- Genomic profile by FoundationOne, Genomic profile by other methods
- Where
- United States
- Volunteers
- 649 people
- Sponsor
- Cota Inc.
Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer
This phase II Lung-MAP treatment trial tests whether carboplatin and pemetrexed with or without selpercatinib works to shrink tumors in patients with RET fusion-positive non-small cell lung cancer that is stage IV or has not…
- Conditions
- Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8
- Trial name
- NCT05364645
- Testing
- Carboplatin, Pemetrexed, Selpercatinib
- Where
- 265 sites in United States
- Sponsor
- SWOG Cancer Research Network
NSCLC, Recurrent, Adenocarcinoma of Lung
Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma
A PHASE I/II TRIAL OF COMBINATION NAB-PACLITAXEL AND NINTEDANIB OR NAB-PACLITAXEL AND PLACEBO IN RELAPSED NSCLC ADENOCARCINOMA
- Trial name
- N3 (NCT03361319)
- Testing
- Vargatef, Abraxane
- Sponsor
- Royal Marsden NHS Foundation Trust
Adaptive Radiotherapy, Stereotactic Body Radiotherapy
Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer or Pulmonary Oligometastases
This study aims to explore the safety and efficacy of eliminating the PTV (planning target volume) margins based on online adaptive stereotactic radiotherapy for patients with early-stage non-small cell lung cancer (NSCLC) or…
- Conditions
- Adaptive Radiotherapy, Stereotactic Body Radiotherapy, Non-small Cell Lung Cancer, Lung Oligometastases
- Trial name
- NCT06542159
- Testing
- Online adaptive SBRT, Conventional SBRT
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Sun Yat-sen University
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy.
- Conditions
- Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Lymphoma
- Trial name
- NCT00003269
- Testing
- sargramostim, amifostine trihydrate, cisplatin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Scripps Health
Carcinoma, Non-Small-Cell Lung
Erlotinib and Sequential Positron Emission Tomography (PET) in Advanced Non Small Cell Lung Cancer (NSCLC)
This is a Phase-II Study to evaluate the accuracy of Fluorodeoxyglucose-/Fluorothymidine-Positron Emission Tomography (FDG-/FLT-PET) analyses for early prediction of non-progression in patients with non-small-cell lung cancer…
- Trial name
- ERLOPET (NCT00568841)
- Testing
- erlotinib, FDG-/FLT-PET
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Lung Cancer Group Cologne
Small Cell Lung Cancer
Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung Cancer
Chiauranib , which simultaneously targets against VEGFR/Aurora B/CSF-1R, several key kinases involved in tumor angiogenesis, tumor cell mitosis, and chronic inflammatory microenvironment.
- Trial name
- NCT04830813
- Testing
- Chiauranib
- Where
- China
- Volunteers
- 184 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
Study of NGM120 in subjects with advanced solid tumors and pancreatic cancer (Part 1 and 2) and metastatic castration resistant prostate cancer (Part 3).
- Conditions
- Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer, Bladder Cancer, Melanoma
- Trial name
- NCT04068896
- Testing
- NGM120 30mg, NGM120 100mg, NGM120 30mg with Gemcitabine and Abraxane
- Where
- 20 sites in United States
- Volunteers
- 89 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Melanoma, Non-small Sell Lung Cancer (NSCLC)
Phase I/II Study of PDR001 in Patients With Advanced Malignancies
The purpose of this "first-in-human" study of PDR001 was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of PDR001 administered i.v.
- Conditions
- Melanoma, Non-small Sell Lung Cancer (NSCLC), Triple Negative Breast Cancer, Anaplastic Thyroid Cancer
- Trial name
- NCT02404441
- Testing
- PDR001
- Where
- 41 sites in United States, Canada and 12 more
- Volunteers
- 319 people
- Sponsor
- Novartis Pharmaceuticals
NSCLC (Advanced Non-small Cell Lung Cancer)
Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK201 for Injection in Combination With Ivonescimab Injection in sqNSCLC Participants.
This is an open-label, multicenter, Phase II clinical study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of ALK201 for Injection combined with Ivonescimab Injection in adult patients with…
- Trial name
- NCT07742956
- Testing
- ALK201 for injection, Ivonescimab Injection
- Volunteers
- 156 people
- Sponsor
- Shanghai Allink Biotherapeutics Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.